Hemogenyx Pharmaceuticals plc has developed a new and improved version of its bispecific antibody CDX for the treatment of relapsed/refractory acute myeloid leukemia, a subset of acute lymphoblastic leukemia, and potentially for conditioning in bone marrow transplantations.
Antibodies targeting cytotoxic T-lymphocyte protein 4 (CLTA-4) have faced challenges due to frequent adverse events and limited efficacy, thus pushing the search for next-generation anti-CTLA-4 antibodies that balance T regulatory cell (Treg) depletion with CD8 T-cell activation for cancer immunotherapy.
Researchers from Shenzhen University and affiliated organizations detailed the preclinical characterization of a synergistic intravesical instillation of fenbendazole (FBZ) and CRISPR-Cas13a-based nanoplatform as a new strategy for the treatment of bladder cancer.
Mestag Therapeutics Ltd. has been awarded a £1.5 million ($1.9 million) grant from Innovate UK’s Cancer Therapeutics program to accelerate the development of MST-0300.
Leukemia inhibitory factor (LIF) is an IL-6 type cytokine involved in the inflammatory response, stem cell self-renewal and tumor progression, that binds to LIFR and gp130 on the cell surface. LIF is overexpressed in several types of cancer such as pancreatic, breast or prostate cancer and thus is considered a therapeutic target for the treatment of cancer.
Invenra Inc.’s bispecific antibody, INV-724, developed for the treatment of neuroblastoma, has been awarded orphan drug and rare pediatric disease designations by the FDA.
Chengdu Duote Antibody Pharmaceutical Co. Ltd. has described antibody-drug conjugates comprising antibody or antigen-binding fragments covalently linked to eribulin derivatives through a linker reported to be useful for the treatment of cancer.
Adcendo ApS and Multitude Therapeutics Inc. have signed a licensing agreement for the development of a highly differentiated antibody-drug conjugate (ADC) targeting tissue factor, designated ADCE-T02.
Medigene AG has provided a pipeline update in its half-year report for the first half of 2024. The company, which develops T cell receptor (TCR)-guided therapies for the treatment of cancer, confirmed for following positive EU and U.S. preliminary regulatory interactions, is on track for filing an IND in Q3 and a CTA in Q4 of 2024 for its lead candidate MDG-1015.
Cidara Therapeutics Inc. announced in its Q2 filing that it received IND clearance for its drug-Fc conjugate (DFC) immunotherapy CBO-421 in July of 2024.
RSS
